e-learning
resources
Munich 2014
Monday, 08.09.2014
COPD exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
S. Bhatt, J. Wells, G. Kinney, G. Washko, Y. I. Kim, W. Bailey, J. Hokanson, E. Silverman, J. Crapo, M. Dransfield (Birmingham, Denver, Boston, United States Of America)
Source:
International Congress 2014 – COPD exacerbations
Session:
COPD exacerbations
Session type:
Oral Presentation
Number:
1933
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Bhatt, J. Wells, G. Kinney, G. Washko, Y. I. Kim, W. Bailey, J. Hokanson, E. Silverman, J. Crapo, M. Dransfield (Birmingham, Denver, Boston, United States Of America). LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene. Eur Respir J 2014; 44: Suppl. 58, 1933
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
LATE-BREAKING ABSTRACT: Predictive factors of frequent exacerbations in mild grade COPD patients
Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care
Year: 2016
Impact of frequent exacerbations in patients with COPD
Source: International Congress 2014 – Clinical presentations
Year: 2014
Mukoregulatory drugs in treating COPD
Source: International Congress 2014 – Predictors
Year: 2014
LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Factors associated with cognitive dysfunction in COPD patients hospitalised with exacerbations
Source: International Congress 2014 – COPD markers
Year: 2014
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014
The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Impact of mucolytic treatment on COPD exacerbations
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Cognitive dysfunction is greater in patients hospitalised with COPD exacerbations than with worsening heart failure
Source: International Congress 2014 – Markers
Year: 2014
Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
LATE-BREAKING ABSTRACT: Biomarkres in exacerbations of chronic obstructive pulmonary disease (ECOPD)
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
LATE-BREAKING ABSTRACT: The Guangzhou COPD exacerbation study: relationship of exacerbations with viral infections and soluble biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Exacerbations in patients with chronic obstructive lung disease (COPD) and concomitant asthma
Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease?
Year: 2014
LATE-BREAKING ABSTRACT: Microbiology and radiology of pneumonia in COPD
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept